Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 2023; 2) the growth of joint products was slightly pressured, and overseas business revenue increased sharply; 3) gross net margin declined slightly, and sales and R&D expenses were steadily declining; 4) operating cash flow performance improved significantly; 5) intensive R&D investment, and the product pipeline was constantly being enriched. (Mainichi Keizai Shimbun)
国信证券4月10日发布研报称，给予春立医疗（688236.SH）买入评级。评级理由主要包括：1）业绩部分受集采影响，2023年归母净利润下滑9.7%；2）关节类产品成长性略有承压，海外业务收入大幅增长；3）毛净利率略有下滑，销售及研发费用率稳中有降；4）经营性现金流表现大幅好转；5）高强度研发投入，产品管线不断丰富。（每日经济新闻）
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 20
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.